Conservative surgery plus brachytherapy treatment for boys with prostate and/or bladder neck rhabdomyosarcoma: a single team experience

Martelli, Hélène; Haie-Méder, Christine; Branchereau, Sophie; Franchi‐Abella, Stéphanie; Ghigna, Maria-Rosa; Dumas, Isabelle; Bouvet, Nathalie; Oberlin, Odile

doi:10.1016/j.jpedsurg.2008.10.040

Cited by 75 publications

(71 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…But one limitation that they report is that this therapy can only be used in children with tumors located in the prostate or the bladder neck. Tumor extension into the bladder must not be above the level of the bladder trigone [17]. A direct comparison with the results to the CWS-96 trial is not possible as low dose brachytherapy was not envisioned by the protocol and most of the tumors in our study were located at higher levels within the bladder.…”

Section: Discussionmentioning

confidence: 85%

Treatment efficiency, outcome and surgical treatment problems in patients suffering from localized embryonal bladder/prostate rhabdomyosarcoma: A report from the cooperative soft tissue sarcoma trial CWS‐96

Seitz¹,

Dantonello²,

Int-Veen³

et al. 2010

Pediatric Blood & Cancer

View full text Add to dashboard Cite

BackgroundTo analyze the clinical course, treatment modalities, complications and outcome of patients suffering from localized embryonal bladder/prostate rhabdomyosarcoma (BPRMS) treated on the CWS‐96 trial.ProcedureThere were 85 patients with BPRMS enrolled and 63 patients with embryonal non‐metastatic BPRMS were analyzed. Fifty‐six patients received neoadjuvant chemotherapy and response was assessed radiographically after 9 weeks. Local therapy with radiation and or surgery was performed based on age, tumor size, and response. Patients were treated with adjuvant chemotherapy following local control.ResultsPatient's age ranged from 0 to 16 years with a median follow up of 5.3 years. Eighty nine percent of the patients had IRS group III disease. The 5‐year overall survival (OS) for the whole group was 76.3 ± 5.6% and the 5‐year event‐free survival (EFS) 69.8 ± 6.2%. Seventeen patients underwent preoperative radiochemotherapy followed by tumor resection (5‐year‐OS: 87.8 ± 8.1%). Eight patients were treated with solely radiochemotherapy (87.5 ± 11.7%). Twenty‐five patients received chemotherapy and tumor resection (OS: 83.6 ± 7.5%). Thirteen patients underwent incomplete tumor resection and were treated with radiochemotherapy postoperatively (OS: 39.9 ± 14.8%, P < 0.05 vs. other groups).ConclusionsLocal therapy is an important factor for prognosis of localized embryonal BPRMS. Inadequate primary or secondary surgery compromises the outcome and should be avoided. Radiotherapy alone, complete surgical tumor resection or combined preoperative radiotherapy with surgical resection lead to similar good local control rates and prognosis. Pediatr Blood Cancer 2011;56:718–724. © 2010 Wiley‐Liss, Inc.

show abstract

Section: Discussionmentioning

confidence: 85%

Treatment efficiency, outcome and surgical treatment problems in patients suffering from localized embryonal bladder/prostate rhabdomyosarcoma: A report from the cooperative soft tissue sarcoma trial CWS‐96

Seitz¹,

Dantonello²,

Int-Veen³

et al. 2010

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…The theoretical disadvantage of BT relies in the inhomogeneous dose distribution with high dose peaks close to the catheters [18]. However, this concern is not supported by the limited data about late effects of BT in children [14,26,43].…”

Section: Discussionmentioning

confidence: 99%

Comparison of different adjuvant radiotherapy approaches in childhood bladder/prostate rhabdomyosarcoma treated with conservative surgery

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Their sexual function could not be assessed due to young age. 21 The overall result suggests that, in selective cases, bladder-sparing surgery plus brachytherapy for boys with prostate or bladderneck RMS may provide improved outcomes of local control and preserve bladder function and thereby maintaining stable survival rate.…”

Section: Organ-sparing Surgerymentioning

confidence: 96%

A Review on Surgical Techniques and Organ Sparing Procedures in Bladder/Prostate Rhabdomyosarcoma

et al. 2014

View full text Add to dashboard Cite

The treatment outcomes in children with bladder/prostate rhabdomyosarcoma (B/P RMS) have considerably improved in the past few decades. Current protocols incorporate chemotherapy, radiotherapy, and surgery (radical or organ sparing). Using this multimodal and multidisciplinary approach, the cure rates for nonmetastatic RMS have gradually increased from 25% in the 1970s, and 70% in the 1990s, to over 80% in the 2000s. Surgery plays a role not only in the diagnosis and management of all stages of B/P RMS, but also in the urinary reconstruction and long-term follow-up. Furthermore, the tendency to avoid mutilating surgery and to preserve functional genitourinary tract has been noticeable. Authors describe the current status and future surgical treatment approaches and possibilities for patients with B/P RMS and how reconstructive urologic surgery in B/P RMS continues to evolve.

show abstract

Conservative surgery plus brachytherapy treatment for boys with prostate and/or bladder neck rhabdomyosarcoma: a single team experience

Cited by 75 publications

References 18 publications

Treatment efficiency, outcome and surgical treatment problems in patients suffering from localized embryonal bladder/prostate rhabdomyosarcoma: A report from the cooperative soft tissue sarcoma trial CWS‐96

Treatment efficiency, outcome and surgical treatment problems in patients suffering from localized embryonal bladder/prostate rhabdomyosarcoma: A report from the cooperative soft tissue sarcoma trial CWS‐96

Comparison of different adjuvant radiotherapy approaches in childhood bladder/prostate rhabdomyosarcoma treated with conservative surgery

A Review on Surgical Techniques and Organ Sparing Procedures in Bladder/Prostate Rhabdomyosarcoma

Contact Info

Product

Resources

About